SIGY (Sigyn Therapeutics) Total Stockholders Equity: $-5.92 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sigyn Therapeutics Total Stockholders Equity?

Sigyn Therapeutics SIGY Total Stockholders Equity is $-5.92 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Sigyn Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $-5.92 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sigyn Therapeutics's Book Value per Share for the quarter that ended in Sep. 2025 was $-3.69. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sigyn Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2025 was -0.48.

Sigyn Therapeutics  (OTCPK:SIGY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sigyn Therapeutics's Book Value per Share for the quarter that ended in Sep. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.917-0)/1.605
=-3.69

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sigyn Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.751 + 2.063) / -5.917
=-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics Total Stockholders Equity Related Terms

Sigyn Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics Total Stockholders Equity Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 -0.27 -1.90 -3.41 -4.46

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.92 -4.46 -4.95 -5.44 -5.92
What does a Total Stockholders Equity of $-5.92 Mil mean?
Sigyn Therapeutics (SIGY) has a Total Stockholders Equity of $-5.92 Mil as of Sep. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sigyn Therapeutics and its competitors.
Is Sigyn Therapeutics' Total Stockholders Equity too high?
Sigyn Therapeutics' current Total Stockholders Equity is $-5.92 Mil.
How does Sigyn Therapeutics' Total Stockholders Equity compare to CNBX and PKTX?
Sigyn Therapeutics' Total Stockholders Equity of $-5.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sigyn Therapeutics and its competitors. Sigyn Therapeutics's current Total Stockholders Equity is $-5.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Total Stockholders Equity of $-5.92 Mil. The current Total Stockholders Equity is $-5.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Total Stockholders Equity is $-5.92 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.